Evaluation of the effect of oral azithromycin on COPD patients

Phase 2

• Conditions: Chronic Obstructive Pulmonary Disease.; Chronic obstructive pulmonary disease, unspecified; J44.9

• Registration Number: IRCT20210405050849N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Diagnosis of COPD by an internal medicine physician, based on the classification of global pioneers of chronic obstructive pulmonary disease (GOLD)
No other chronic diseases such as orthopedic and motor diseases, multiple sclerosis or cancer.
hospitalization
stability of the patient's physical and mental condition

Exclusion Criteria

Lack of motivation of the patient to cooperation
Immune system defects (recurrent respiratory infections and worsening of shortness of breath)
Existence of concomitant asthma
Complications of azithromycin
non-pulmonary diseases like cancer; liver dysfunction, cholestatic jaundice,
Infiltration and consolidation in chest x-ray
Patients with acute exacerbation of COPD
Existence of atopy or allergic rhinitis
pneumonia
embolism
Kidney failure
hearing loss

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FEV1/ FVC. Timepoint: Two months after starting the study. Method of measurement: Spirometry.